Last reviewed · How we verify

NCT05461820

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

Recruiting now Phase 4 Last updated 11 December 2023
What this trial tests

Phase 4 trial testing Methimazole in Graves Disease in 240 participants. Currently enrolling.

Timeline
1 May 2018
Primary endpoint
31 December 2023
31 July 2030

Quick facts

Lead sponsorThe First Affiliated Hospital with Nanjing Medical University
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment240
Start date1 May 2018
Primary completion31 December 2023
Estimated completion31 July 2030
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 65, any sex, with Graves Disease or Relapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Serum metabolomics reveals systemic metabolic alterations of Graves' disease before and after antithyroid drug treatment.
    Li T, Li L, Wang X, Li Y, et al · · 2025 · PMID 40465360 · DOI 10.1530/ec-25-0078

Verify or expand the search:

Other trials of Methimazole

Trials testing the same drug.

Other recruiting trials for Graves Disease

Currently open trials in the same condition.

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05461820.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing